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Abstract
Background: Bipolar illness is associated with significant psychosocial morbidity and health resource utilization.
Second generation antipsychotics, used alone or in combination with mood stabilizers are effective in treating
acute mania in community settings. This study was designed to compare the change in clinical parameters and
resource utilization at one month in a group of patients who required treatment intervention for exacerbation of
mania. The clinical response at one year was also evaluated.
Methods: 496 patients were enrolled at 75 psychiatric practices across Canada. The Olanzapine cohort (n = 287)
included patients who had olanzapine added to their medication regimen or the dose of olanzapine increased.
The Other cohort (n = 209) had a medication other than olanzapine added or the dose adjusted. Changes from
baseline in the Young Mania Rating Scale (YMRS), Montgomery Asberg Depression Rating Scale, Beck Anxiety
Inventory and SF-12 Health Survey were compared at one month using ANCOVA. Categorical variables at one
month for health resource utilization, employment status, abuse/dependency, and the number of suicide attempts
were compared using Fisher’s Exact test. Patients were followed for one year and a subgroup was evaluated.
Results: At one month, patients in the Olanzapine cohort recorded a mean reduction in the YMRS of 11.5,
significantly greater than the mean reduction in the Other cohort of 9.7 (ANCOVA P = 0.002). The Olanzapine
cohort was significantly improved compared to the Other cohort on the scales for depression and anxiety and did
not experience the deterioration in physical functioning seen in the Other cohort. No significant differences were
detected in health-related quality-of-life measures, employment status, drug abuse/dependency, number of suicide
attempts, mental functioning, emergency room visits or inpatient psychiatric hospitalizations. In a subgroup treated
for 12 months with a single second generation antipsychotic, improvements in illness severity measures were
maintained with no evidence of significant differences among the antipsychotics.
Conclusions: Patients with bipolar disorder requiring treatment intervention for exacerbation of mania in the
community setting responded to olanzapine at one month. In a subset analysis, second generation antipsychotic
treatment continued to be beneficial in reducing bipolar symptoms at one year.
Background
Bipolar disorder is a chronic lifelong illness with many
individuals experiencing a relapsing and remitting
course. In patients treated for bipolar disorder, relapse
rates range from 40% to 60%, making intervention for
exacerbation a common necessity [1]. Bipolar illness is
associated with significant psychosocial morbidity [2],
impacting employment and health resource utilization.
In Canada, the recommended first-line pharmacologi-
cal treatment for symptoms of acute mania in patients
already on therapy is the addition of lithium or dival-
proex, or a second generation antipsychotic (SGA), or a
combination of the two [3]. For non-responsive or relap-
sing patients already on a SGA, switching to a different
SGA or adding lithium are recommended [3]. This
s t u d yf o c u s e do nt h eu s eo ft h eS G Ao l a n z a p i n ew h i c h
has been shown to be effective in patients who failed to
respond adequately to lithium or valproate monotherapy
[4]. SGAs (including olanzapine, risperidone and quetia-
pine) alone or in combination with mood stabilizers
have been reported to be effective in acute mania [3-5].
Clinical trials that demonstrate efficacy and safety for
drug approval are randomized and controlled with
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any medium, provided the original work is properly cited.rigorous patient inclusion criteria. They typically exclude
patients with comorbid conditions, substance abuse or
concurrent therapy. These studies may not fully reflect
the population that ultimately receives drugs in commu-
nity-based clinical practice [6]. Observational studies
can give valid results in real-world clinical settings and
can expand the generalizability of results derived from
controlled clinical trials [6,7].
The CNS-Bipolar (Canadian Naturalistic Study –
Bipolar Disorder) was designed as a non-interventional,
naturalistic, observational study of health outcomes in
community-based patients with bipolar disorder receiv-
ing routine psychiatric care. Specifically, the study was
designed to provide information not often found in ran-
domized clinical trials including: i) one-month outcomes
of Canadian patients with bipolar disorder treated in a
community-based setting, ii) outcomes in patients with
substance abuse and other comorbid conditions, iii)
one-year outcomes of patients with bipolar disorder
treated under naturalistic conditions in the community,
iv) concomitant medications that may be prescribed to
patients with bipolar disorder, and v) the impact of
treatment on inpatient hospital days and emergency
room visits.
The primary objective of CNS-Bipolar was to measure
the change in mania symptoms from baseline to
approximately one month to capture the response to
treatment intervention for an exacerbation of mania.
Two cohorts were followed: those in the Olanzapine
cohort were prescribed an increase in dose or addition
of olanzapine and those in the Other cohort were pre-
scribed a change in dose or addition of a psychotropic
medication other than olanzapine. The Young Mania
Rating Scale (YMRS) [8] was used to measure the symp-
toms of mania as it is a valid [8] and well recognized
tool [9]. The secondary objectives included measuring
response to therapy at one month, degrees of anxiety
and depression, health-related quality of life, health
resource utilization, and the use of concomitant medica-
tions. Patients were then followed for one year and trea-
ted as clinically required in an outpatient community
setting.
This article describes the statistical comparison of the
cohorts at one month. Outcomes at one year are pre-
sented for the study group as a whole.
Methods
The study was a one-year, prospective, observational
study of the clinical and health outcomes of commu-
nity-based outpatients with bipolar disorder who
required an adjustment in medication due to exacerba-
tion of mania. The study collected data from 75 psychia-
trists practicing in community settings across nine
Canadian provinces between April 2003 and March
2005. It was non-interventional in that psychiatrists’
decisions regarding treatment were made in the course
of routine clinical care and clinic visits every six months.
Prior to study initiation, appropriate local ethics com-
mittee approval and written informed consent from
each patient were obtained. The study was conducted in
accordance with the principles of the Declaration of
Helsinki [10].
Two treatment cohorts were evaluated. The Olanza-
pine cohort included patients whose psychiatrist had
made the decision to increase the dose of olanzapine or
add olanzapine in response to exacerbation of manic
symptoms. The Other cohort included patients whose
psychiatrist had made the decision to change the dose
of a current medication prescribed for bipolar disorder
or add another medication (other than olanzapine) in
response to exacerbation of manic symptoms. Participat-
ing psychiatrists were requested to enroll approximately
60% into the Olanzapine cohort and 40% into the Other
cohort, although the final ratio of patients was left to
the psychiatrists’ discretion (i.e., all or none of an inves-
tigator’s patients could potentially be enrolled into the
Olanzapine or Other cohort). All decisions on medica-
tion were made in the course of normal, ongoing patient
care and no inducements that might influence prescrip-
tion choice were provided.
Patients were eligible for the study if they met all of
the following criteria: a) presented with bipolar disorder
based on Diagnostic and Statistical Manual Version IV
(DSM IV) criteria [11]; b) were being treated by a psy-
chiatrist in a community-based office setting; c) were
aged 18 years or older; d) were considered by their
psychiatrist to be demonstrating manic symptoms and
as a result required a change in their ongoing therapy
and; e) were capable of providing informed consent for
study participation. Patients were excluded from the
study if they were receiving olanzapine therapy for bipo-
lar disorder and no dose adjustment of olanzapine was
required, or presented for treatment in a hospital psy-
chiatric emergency setting or were considered urgent
candidates for hospitalization.
To evaluate treatment outcomes, data was collected at
time of medication change (baseline), four to six weeks
post baseline (One Month), 22 to 30 weeks post baseline
(Six Months), and 48 to 56 weeks post baseline (One
Year) during the course of routine psychiatric visits.
Clinical outcomes were evaluated by measuring reduc-
tion in illness severity and psychopathology with the
YMRS [8], the Montgomery Asberg Depression Rating
Scale (MADRS) [12], and the patient-completed Beck
Anxiety Inventory (BAI) [13]. A priori, treatment
response for a patient was defined as a YMRS score ≤ 8
(from a baseline score of ≥ 9) and MADRS score ≤ 14
at one month. Improvements in health-related outcomes
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Survey (the SF-12 is an abbreviated version of the SF-36
Health Survey) [14] which assesses patients’ health-
related quality of life using physical and mental compo-
site scores and has been shown to be a valid measure in
bipolar disorder [15].
Data was also collected on demographic variables, cur-
rent comorbid conditions, work status, number of sui-
cide attempts, psychiatric hospitalizations, use of
psychiatric emergency services, concomitant medications
and substance abuse/dependency. Investigators were
required to report any serious adverse events for
patients taking olanzapine, which were defined as events
resulting in death, inpatient hospitalization or prolonged
hospitalization, life-threatening events or those causing
severe or permanent disability. Nonserious adverse
events were not collected.
Statistical analysis
The study was planned with 87% power to detect a dif-
ference in YMRS mean of 3.0 at one month (assuming
an SD of 10.0) with 270 patients in the Olanzapine
cohort and 180 patients in the Other cohort. Total
scores were calculated for the YMRS (primary outcome
variable), MADRS and BAI. The SF-12 physical (PCS-
12) and mental (MCS-12) composite scores were
derived and standardized to a mean of 50 and an SD of
10 in the 1998 general US population [14]. If one or
more items of a scale were missing, the total score was
considered missing. By a priori definition, only patients
with baseline YMRS ≥ 9 were evaluated for potential
response. For these patients, response was defined as a
YMRS score ≤ 8 and MADRS score ≤ 14 at one month.
Baseline comparisons between the two cohorts were
performed using Fisher’s Exact tests for categorical vari-
a b l e sa n dA N O V Am o d e l sw i t ht h e r a p yg r o u pa n ds i t e
as terms for the dependent variables age, weight and the
YMRS, MADRS, BAI, PCS-12 and MCS-12 totals. Sites
with less than five subjects were pooled by region.
For the clinical (YMRS, MADRS, BAI) and health sur-
vey (PCS-12, MCS-12) outcomes, least-squares means
and 95% confidence intervals were generated at baseline
and at one month from ANOVA models with therapy
cohort and site (pooled) as terms.
Changes from baseline to one month in the clinical
and health survey outcomes were calculated for all
patients with relevant data. Differences in the change
scores between the Olanzapine and Other cohorts were
tested using an ANCOVA model with the change score
as the dependent variable and therapy group, site
(pooled), and baseline value as the independent vari-
ables. Least-squares means and 95% confidence intervals
were generated from the ANCOVA models for change
and for the between therapy group difference in change.
Change in weight over the first month was analyzed in
the same way as change in the clinical and health survey
outcomes. Categorical variables at one month were
compared between therapy cohorts using Fisher’sE x a c t
test.
Befitting an observational study, physicians were free
to modify drug regimens as they felt appropriate after
baseline and could add to or drop from either cohort
any of the prescribed psychotropic medications. Due to
this, comparisons of the two cohorts after one year may
not be meaningful. As an exploratory investigation,
patients who initiated or changed to olanzapine, quetia-
pine or risperidone at baseline, and who also completed
the full 12 months of treatment with the single SGA
assigned at baseline, were selected as a subgroup. Pro-
pensity adjusted [16] ANCOVA models controlling for
investigative site and baseline levels of the outcome,
were used to compare YMRS, MADRS and BAI in the
three drug groups. Least-squares means and 95% confi-
dence intervals for change from baseline were calcu-
lated. The propensity scores used in the ANCOVA
model were the conditional probabilities of being treated
with each of the drugs given the individual’s baseline
covariates, and were obtained from a polytomous logis-
tic model for treatment cohort using as predictors: base-
line patient characteristics, health status indicators,
utilization of psychiatric and emergency services, and
drug and alcohol dependence or abuse indicators.
Results
A total of 496 patients were enrolled into the study, 287
patients in the Olanzapine cohort and 209 patients in
the Other cohort (Figure 1).
Demographic and baseline characteristics are shown in
Table 1. Subjects were in their early 40s on average,
mostly Caucasian, weighed about 80 kg on average and
more than half were female. The cohorts were very
similar on all measures of bipolar illness severity and
u s eo fp s y c h i a t r i cr e s o u r c e s( T a b l e1 ) .T h em o s tc o m -
mon comorbid conditions (reported in >7%) were
hypothyroidism, hypertension and diabetes, with 35%
(101/287) in the Olanzapine cohort and 40% (84/209) in
the Other cohort reporting at least one medical condi-
tion in addition to bipolar disorder.
At baseline, 38% (107/283) in the Olanzapine cohort
and 36% (74/205) in the Other cohort were employed
(Table 1), with 47% (47/101) in the Olanzapine cohort
a n d3 6 %( 2 4 / 6 6 )i nt h eO t h e rc o h o r tr e p o r t i n gm i s s e d
work days.
Clinical results at one month
At one month, 94% (n = 270) of patients in the Olanza-
pine cohort and 96% (n = 200) of patients in the Other
cohort remained in the study.
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Table 1 Baseline characteristics of enrolled patients
Characteristics Olanzapine (n = 287) Other (n = 209) P value
Female 55% 67% 0.009
Caucasian 93% 88% 0.038
Mean age, years (SD) 41.7 (12.0) 40.2 (11.5) 0.884
Mean weight, kg (SD) 79.4 (17.3) 82.8 (21.3) 0.048
Smoking status, Yes 47% 41%
At least one comorbid medical condition 35% 40%
Work status:
- employed 38% 36%
- missed work days 47% 36%
Past suicide attempts, Yes 39% 35%
Baseline Illness Severity LS mean (95% CI)
YMRS Total 19.0 (18.2 to 19.8) 19.4 (18.4 to 20.4) 0.524
MADRS Total 14.4 (13.5 to 15.3) 13.5 (12.4 to 14.6) 0.186
BAI Total 14.8 (13.4 to 16.2) 15.3 (13.6 to 17.0) 0.658
SF-12:
- Physical Composite 50.6 (49.2 to 51.9) 50.5 (48.8 to 52.1) 0.930
- Mental Composite 38.5 (37.0 to 39.9) 37.0 (35.3 to 38.7) 0.189
Psychiatric Hospitalizations and Use of Psychiatric Emergency Services
Patients Reporting Use in Last 6 Months
Psychiatric Emergency Room Visits 20% 20%
Inpatient Admissions 21% 21%
Lifetime Inpatient Admissions 65% 61%
YMRS: Young Mania Rating Scale
MADRS: Montgomery Asberg Depression Rating Scale
BAI: Beck Anxiety Inventory
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YMRS score from baseline to one month. In the Olanza-
pine cohort a mean reduction in the YMRS of 11.5 (95%
CI -12.2 to -10.7) was recorded at one month. The
change represented a reduction from a mean YMRS at
baseline of 19.0 (95%CI 18.2 to 19.8) to a mean at one
month of 7.4 (95%CI 6.7 to 8.2) (Figure 2). In the Other
cohort a mean reduction of 9.7 was recorded (95%CI
-10.6 to -8.8) representing a reduction from a mean of
19.4 (95%CI 18.4 to 20.4) to a mean of 9.3 (95%CI 8.4
t o1 0 . 2 )( F i g u r e2 ) .T h er e d u c t i o ni nm e a nY M R Sf r o m
baseline in the Olanzapine cohort was significantly
greater compared to the Other cohort with a difference
of -1.8 (95%CI -2.9 to -0.6, ANCOVA, P = 0.002).
In the Olanzapine cohort 44% (95%CI 37.3 to 50.3)
met the a priori criterion for response, significantly
more than the 34% (95%CI 26.5 to 40.6) in the Other
cohort (Fisher’s Exact test, P = 0.049).
Figure 2 shows the reductions in mean scores on the
YMRS, MADRS and BAI for both cohorts at one
month. On the MADRS, a mean reduction of 3.9 (95%
CI -5.0 to -2.9) was found in the Olanzapine cohort at
one month, while in the Other cohort a mean reduction
of 2.3 (95%CI -3.5 to -1.1) was found (ANCOVA,
P = 0.031). On the BAI the Olanzapine cohort recorded
a mean reduction of 4.9 (95%CI -6.1 to -3.7) at one
month while in the Other cohort a mean reduction
of 2.6 (95%CI -4.0 to -1.2) was found (ANCOVA,
P = 0.012).
Health outcomes at one month
A reduction on the physical composite scale of the SF-
12 was seen in the Other cohort at one month, reflect-
ing deterioration, which was not seen in the Olanzapine
cohort (mean reduction in Olanzapine cohort 0.0, 95%
CI -1.1 to 1.1, mean reduction in Other cohort 1.7, 95%
CI -3.0 to -0.5, ANCOVA P = 0.036). On the mental
composite scale of the SF-12, improvements were
recorded for both cohorts at one month, although the
change from baseline did not differ significantly between
the groups (mean improvement in Olanzapine cohort
3.4, 95%CI 2.0 to 4.9, mean improvement in Other
cohort 2.1, 95%CI 0.5 to 3.8, ANCOVA P =0 . 2 3 6 ) .A t
one month, 1.5% (4/267) in the Olanzapine cohort and
Figure 2 Least-squares mean scores for YMRS, MADRS, and BAI at baseline and one month. YMRS: Young Mania Rating Scale. MADRS:
Montgomery Asberg Depression Rating Scale. BAI: Beck Anxiety Inventory.
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suicide attempt in the past 30 days.
At one month, no differences in the employment mea-
sures were detected between the groups with 34% (90/
268) in the Olanzapine cohort and 34% (64/191) in the
Other cohort employed and 36% (20/56) in the Olanza-
pine cohort and 30% (14/46) in the Other cohort report-
ing missed work days.
In the first month, 4% (12/268) in the Olanzapine
cohort required inpatient psychiatric hospitalization,
not significantly different from the 6% (11/198) in the
Other cohort. The number requiring psychiatric emer-
gency room visits was also similar; 3% (9/267) in the
Olanzapine cohort and 4% (8/197) in the Other
cohort.
No obvious differences were found in the number of
patients abusing alcohol and/or cannabis at one month
(alcohol abuse in Olanzapine cohort 11%, 27/253, in
Other cohort 8%, 15/193: cannabis abuse in Olanzapine
cohort 6%, 14/252, in Other cohort 5%, 9/191).
Patients in both cohorts gained weight by one month,
but the increase in weight did not significantly differ
between the two groups (ANCOVA P = 0.5215). The
Olanzapine cohort gained a mean of 1.2 kg (95%CI 0.3
to 2.1) while the Other cohort gained a mean of 1.7 kg
(95%CI 0.6 to 2.8).
Treatment patterns at one month
SGA use remained stable over the first month in both
groups. At one month 245 were taking olanzapine (86%,
232/270 in Olanzapine cohort and 7%, 13/200 in Other
cohort), 62 were taking quetiapine (1%, 4/270 in Olanza-
pine cohort and 29%, 58/200 in other cohort) and 81
were taking risperidone (1%, 3/270 in Olanzapine cohort
and 39%, 78/200 in Other cohort).
Table 2 captures the use of SGAs, mood stabilizers
and selective serotonin reuptake inhibitors/selective ser-
otonin and norepinephrine reuptake inhibitors (SSRIs/
SNRIs). The pattern of psychotropic drug use for the
combinations captured is similar, with the combination
of a SGA and mood stabilizer being the most common
(used by 33%, 90/270 in the Olanzapine cohort and
30%, 60/200 in the Other cohort at one month).
Outcomes at one year
Over the course of one year, psychiatrists were free to
alter psychotropic medication as clinically required,
resulting in mixed medication profiles for both groups.
For this reason one-year results are not presented by
the treatment cohorts defined for the one-month analy-
sis. A total of 377 patients completed the one-year
study. Patients discontinued for the reasons summarized
in Figure 1.
One patient taking olanzapine died following the one-
month visit but before the six-month visit (Figure 1),
although the death was deemed by the investigator to
be unrelated to olanzapine. Twenty-one patients taking
olanzapine were hospitalized for adverse events: six for
depression, six for bipolar disorder, three for suicidal
ideation/attempt, two for mania, one for hypomania,
one for psychosis, one for agitation, and one for hypona-
tremia. One relapse of depression was deemed possibly
related to olanzapine, while all other events were con-
sidered not drug related. Psychiatrists were not required
to report hospitalizations or other serious events for
patients taking SGAs other than olanzapine. Over the
course of the year, six patients discontinued due to
adverse events (Figure 1).
Changes in the YMRS, MADRS and BAI between
baseline and one year were analyzed by single SGA used
Table 2 Use of second generation antipsychotics, mood stabilizers and SSRI/SNRIs
†
Medication* Baseline One Month
Olanzapine
(n = 287)
Other
(n = 209)
Olanzapine
(n = 270)
Other
(n = 200)
SGA + Mood
Stabilizer
97 (34%) 55 (26%) 90 (33%) 60 (30%)
SGA Alone 87 (30%) 42 (20%) 75 (28%) 37 (19%)
SGA + SSRI/SNRI 51 (18%) 23 (11%) 43 (16%) 30 (15%)
SGA + SSRI/SNRI +
Mood Stabilizer
34 (12%) 24 (11%) 39 (14%) 27 (14%)
Mood Stabilizer Alone 8 (3%) 38 (18%) 7 (3%) 28 (14%)
Mood Stabilizer + SSRI/SNRI 5 (2%) 13 (6%) 6 (2%) 8 (4%)
SSRI/SNRI Alone 3 (1%) 8 (4%) 3 (1%) 3 (2%)
SGA: second generation antipsychotic
†SSRI/SNRIs: selective serotonin reuptake inhibitors/selective serotonin and norepinephrine reuptake inhibitors: includes citalopram, fluoxetine, paroxetine and
venlafaxine
Mood Stabilizer: includes lithium and valproate
*In addition patients may have used benzodiazepines and/or tricyclics
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SGA, but those taking combination SGAs were
excluded). An adjustment using the propensity method
for the probability of being assigned a specific single
SGA was effective in reducing bias due to baseline vari-
ables. While treatment with a single SGA was associated
with improvements on the YMRS, MADRS and BAI at
one year, there were no significant differences in the
degree of improvement among patients treated with
olanzapine, risperidone and quetiapine (Table 3). For
t h eS F - 1 2 ,t r e a t m e n tw i t has i n g l eS G Aw a sa s s o c i a t e d
with improvements on the mental but not the physical
composite score at one year, with no significant differ-
ences in the degree of improvement among patients
treated with olanzapine, risperidone and quetiapine.
Discussion
The overall purpose of CNS-Bipolar was to study out-
comes at one month in bipolar disorder following a
change in pharmacological treatment for exacerbation of
mania in the outpatient psychiatric setting. Community-
based settings capture all presenting patients, regardless
of comorbid conditions – in this study 35 to 40% of the
patients enrolled had at least one comorbid medical
condition. The heterogeneity of previous history, treat-
ment protocols and investigators will all influence out-
comes. Clinically meaningful reductions in YMRS scores
were observed in both treatment groups at one month
(11.5 for the Olanzapine cohort and 9.7 for the Other
cohort). The absolute YMRS scores at one month were
7 . 4f o rt h eO l a n z a p i n ec o h o r ta n d9 . 3f o rt h eO t h e r
cohort. YMRS scores below 12 are generally considered
a clinical indicator of remission [4,17]. Patients in the
Olanzapine cohort recorded a significantly greater mean
reduction in the YMRS of 11.5 compared to the Other
cohort (mean reduction of 9.7), and significantly more
patients in the Olanzapine cohort responded to treat-
ment (44%) compared to the Other cohort (34%).
In this study, psychiatrists were free to modify drug
regimens as they felt appropriate and could add olanza-
pine to regimens of the Other cohort or add another
SGA to regimens of the Olanzapine cohort. A SGA and
Table 3 Mean change in YMRS, MADRS, BAI and SF-12 at one year by single SGA received
Single SGA
Received
LS Mean for
Change from
Baseline to
One Year with
Propensity Adjustment
95% Confidence Interval P value*
YMRS
olanzapine (n = 154) -15.9 -16.7 to -15.2 0.835
risperidone (n = 41) -15.9 -17.3 to -14.5
quetiapine (n = 38) -15.5 -16.9 to -14.1
MADRS
olanzapine (n = 154) -7.5 -8.8 to -6.2 0.552
risperidone (n = 42) -6.2 -8.7 to -3.7
quetiapine (n = 37) -7.8 -10.4 to -5.3
BAI
olanzapine (n = 132) -7.0 -8.4 to -5.6 0.935
risperidone (n = 34) -6.9 -9.7 to -4.1
quetiapine (n = 32) -6.4 -9.4 to -3.5
SF-12 Mental Composite
olanzapine (n = 127) 6.3 4.0 to 8.7
risperidone (n = 37) 5.0 0.5 to 9.5 0.057
quetiapine (n = 31) 11.9 7.1 to 16.8
SF-12 Physical Composite
olanzapine (n = 127) 0.6 -1.4 to 2.5 0.077
risperidone (n = 37) -0.7 -4.4 to 3.0
quetiapine (n = 31) -4.4 -8.4 to -0.5
SGA: second generation antipsychotic
YMRS: Young Mania Rating Scale
MADRS: Montgomery Asberg Depression Rating Scale
BAI: Beck Anxiety Inventory
*P value from F-test for any differences among the effects of the three single SGAs
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tion used at one month (30 to 33% of patients) and con-
sistent with the clinical practice guidelines for the
treatment of acute mania [3]. Tohen documented a
YMRS reduction of 13.1 at six weeks when olanzapine
was added to lithium or valproate compared to a reduc-
tion of 9.1 on mood stabilizers alone [4]. A literature
review [18] and meta-analyses [17,19] have found olan-
zapine cotherapy to be superior to monotherapy on
measures of treatment response, change in YMRS, and
treatment withdrawal.
In addition to improvements in mania symptoms,
improvements in depression and anxiety were reflected
in both cohorts on the MADRS and BAI. Improvements
in the Olanzapine cohort were significantly greater than
the improvements recorded in the Other cohort on both
measures. The improvement was consistent with
changes recorded in the Hamilton Depression Rating
Scale at six weeks in patients taking combined olanza-
pine and a mood stabilizer [4,20]. On the other hand, a
review of six olanzapine trials [9] found olanzapine to
be no more efficacious than divalproex in reducing
depressive symptoms.
According to the physical component of the SF-12,
the Other cohort demonstrated deterioration in the first
month; this was not seen in the Olanzapine cohort. In
contrast, Namjoshi found that olanzapine treatment
alone [21,22] or combined with a mood stabilizer [20]
improved physical functioning in acute mania. Patients
in both treatment cohorts experienced improvement in
the mental component score on the SF-12 but there was
no significant between-group difference in the degree of
improvement. Our study results may reflect a pattern
identified by Namjoshi [21] who found that symptom
reduction (reflected in a 10-point reduction in the
YMRS) can occur within three weeks with olanzapine
treatment, while improvements on health-related qual-
ity-of-life measures take longer to achieve. After review-
ing the quality-of-life literature in bipolar disorder,
Michalak [15] concurred – clinical symptoms and mea-
sures of physical functioning could improve with acute
treatment while other quality-of-life measures could
take up to a year to register an improvement.
This pattern may explain the failure to detect at one
month any meaningful changes in employment status or
number of missed work days, emergency room visits,
inpatient hospitalization, suicide attempts, or the use/
abuse of cigarettes, alcohol or cannabis. Others have
recorded improvements in work status after 12 weeks of
olanzapine treatment [22].
Weight gain of 1 to 2 kg was recorded in both treat-
ment groups at one month but did not significantly dif-
fer between the groups. The gain appears to be less
than that reported in studies that used olanzapine in
combination with mood stabilizers (2.9 kg [19], 3.1 kg
[4]), and similar to the gains when olanzapine was used
as monotherapy (2.1 kg gain found in a four-week olan-
zapine vs. placebo controlled clinical trial [23], 1.65 kg
gain in three placebo-controlled monotherapy trials [9])
Retention rates were high in this study and consistent
with rates reported in a review of controlled olanzapine
trials [9], although others have reported high withdrawal
rates in the bipolar population [19]. Over 75% of
patients remained on therapy for one year which at least
in part may be attributable to patient and investigator
perceived clinical improvements in manic, depressive
and anxiety symptoms and the flexibility psychiatrists
had to alter medication as required.
Following a year of community-based treatment, it
was only possible to consider outcomes by treatment
received and patients were grouped by single SGA used
(those receiving multiple SGAs were excluded). In this
exploratory subgroup analysis the improvements in
bipolar symptoms seen in these patients at one month
were maintained at one year and there were no signifi-
cant differences among patients treated with olanzapine,
risperidone or quetiapine. These results are consistent
with a meta-analyses of SGA monotherapy which found
no significant differences between SGAs [17].
Similarly, significant differences were not seen in the
health-related quality-of-life outcomes between olanza-
pine, risperidone or quetiapine when used as a single
SGA over one year. In keeping with the one-month
results, mental functioning was improved but an
improvement was not seen in physical functioning.
These results fail to replicate those of Namjoshi who
found improvements in quality-of-life measures follow-
ing one year of open-label olanzapine treatment [21].
There were a number of limitations presented by this
study design. Patients in the Other cohort may have
received olanzapine and patients in the Olanzapine
cohort may have received other SGAs. At one month
the degree of mixing of medication was small. At one
year patients were grouped by monotherapy used; how-
ever, the study had low power for this exploratory analy-
sis. The primary efficacy measure (YMRS) was scored by
the investigator. Inherent in observer rated open-label
studies is the risk of performance bias. Another limita-
tion was that the reporting of nonserious adverse events
was at the discretion of the investigator and was not
mandatory in this observational study. Serious adverse
events were only reported for those in either cohort tak-
ing olanzapine.
Conclusions
CNS-Bipolar involved a large sample of community-
based patients with a diagnosis of bipolar disorder
experiencing an exacerbation of manic symptoms. It had
Sagman et al. BMC Psychiatry 2010, 10:24
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Page 8 of 10broad inclusion criteria and enrolled patients with
comorbid conditions, substance abuse/dependency and a
wide variety of concomitant medications. Patients who
were prescribed olanzapine or required a change in dose
of olanzapine demonstrated significantly greater
improvements in manic, depressive and anxiety symp-
toms at one month compared to others who received
different therapeutic intervention for mania. At one
month no prominent improvements in health-related
quality-of-life measures were observed and the number
of suicide attempts, rate of alcohol and cannabis use
and the use of health care resources were similar in the
Olanzapine cohort and Other cohort. At one year the
improvements in bipolar symptoms were maintained,
although there was no association with the type of SGA
used.
The results suggest that adjunctive olanzapine may be
clinically beneficial in the community setting for the
treatment of acute mania, with improvements in bipolar
symptoms detected at one month. In a subset analysis,
SGA treatment continued to be beneficial in reducing
bipolar symptoms at one year. Intervention that achieves
fast, measurable and lasting results on symptoms of
mania, depression and anxiety is of clinical advantage in
bipolar patients.
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